Irinotecan Fair-Med (Irinotecan Hydrochloride Trihydrate)

Irinotecan Fair-Med is employed in the management of colorectal cancer and related disease stages, acting on tumor cells that rely on topoisomerase I activity.

• Colorectal cancer: used in combination regimens to shrink primary tumors and improve survival.
• Metastatic colorectal cancer: administered to control disease spread and extend patient lifespan.
• Advanced colorectal cancer: incorporated into second‑line therapy when first‑line options have failed.

• Irinotecan is a pro‑drug that is converted intracellularly to SN‑38, a potent inhibitor of DNA topoisomerase I. By stabilising the enzyme‑DNA cleavable complex, it prevents relegation of single‑strand breaks, leading to accumulation of DNA damage and ultimately tumor cell death during replication.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring during or after infusion.
• Diarrhea: often delayed, may require antidiarrheal therapy.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: temporary hair loss during treatment cycles.
• Fatigue: generalized tiredness affecting daily activities.
• Anemia: decreased red blood cell production leading to low hemoglobin.

Serious or Rare Side Effects

• Febrile neutropenia: fever with severe neutropenia requiring urgent care.
• Severe colitis: intense, bloody diarrhea that can be life‑threatening.
• Allergic reactions: rash, bronchospasm, or anaphylaxis.
• Hepatic toxicity: elevated liver enzymes or jaundice.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Severe electrolyte disturbances: hypokalemia or hyponatremia.

Prior to initiating Irinotecan Fair-Med, clinicians should evaluate several safety parameters.

• Baseline blood counts: monitor for neutropenia and anemia throughout therapy.
• Liver function: assess hepatic enzymes as impairment may increase drug exposure.
• Biliary obstruction: avoid in patients with known blockage to reduce risk of severe diarrhea.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce irinotecan exposure.
• UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 levels and toxicity.
• Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs: may exacerbate constipation associated with irinotecan.
• Warfarin: potential alteration of INR requiring closer coagulation monitoring.
• Fluoropyrimidines (e.g., 5‑FU): additive gastrointestinal toxicity may necessitate dose adjustments.